Overall Symptoms After BNT162b2, Other Vaccines Comparable in <5s
THURSDAY, Oct. 27, 2022 (HealthDay News) -- Among children younger than 5 years, guardian-reported symptoms after BNT162b2 administration were generally comparable to those for on-label non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, according to a study published online Oct. 20 in JAMA Network Open.
Nicole Toepfner, M.D., from the Technische Universität Dresden in Germany, and colleagues conducted a retrospective assessment of the safety of the BNT162b2 vaccine used off-label in children younger than 5 years compared with the safety of other vaccines in the same sample. Short-term safety data were presented for children receiving one to three doses of 3- to 10-μg BNT162b2. A total of 7,806 children were included in the study, and they were followed for a mean of 91.4 days since first BNT162b2 vaccination.
The researchers found that compared with lower doses, a 10-μg dosage was more frequently associated with local injection-site symptoms. In the active comparator analysis, the probability of any symptoms, local symptoms, musculoskeletal symptoms, dermatologic symptoms, or otolaryngologic symptoms was elevated after BNT162b2 versus non-SARS-CoV-2 vaccines (odds ratios, 1.62, 1.68, 2.55, 2.18, and 6.37, respectively), while lower probabilities of general symptoms and fever were seen after BNT162b2 (odds ratios, 0.77 and 0.42, respectively). At BNT162b2 dosages above 3 μg, symptoms requiring hospitalization were reported.
"These data may be helpful in safety considerations for individual decision-making and may add to data expected from prospective licensure studies for expert recommendations about BNT162b2 vaccinations in this age group," the authors write.
Related Posts
Lymph Node Dissection Declining in SLN-Positive Melanoma
WEDNESDAY, March 9, 2022 (HealthDay News) -- For patients with sentinel lymph...
Sacar a los niños a la naturaleza mejora la salud pulmonar, encuentra un estudio
MIÉRCOLES, 27 de julio de 2022 (HealthDay News) -- Vivir cerca de la naturaleza...
Renuncia el principal funcionario de la FDA implicado en el fiasco de la fórmula infantil
JUEVES, 26 de enero de 2023 (HealthDay News) -- El miércoles, un funcionario de...
Rate of Opioid Rx at Discharge From Emergency Department Declining
FRIDAY, Jan. 20, 2023 (HealthDay News) -- From 2017-2018 to 2019-2020, there has...